[go: up one dir, main page]

DK200101859A - Farmaceutiske formuleringer og fremgangsmåder omfattende intranasal morfin - Google Patents

Farmaceutiske formuleringer og fremgangsmåder omfattende intranasal morfin Download PDF

Info

Publication number
DK200101859A
DK200101859A DK200101859A DKPA200101859A DK200101859A DK 200101859 A DK200101859 A DK 200101859A DK 200101859 A DK200101859 A DK 200101859A DK PA200101859 A DKPA200101859 A DK PA200101859A DK 200101859 A DK200101859 A DK 200101859A
Authority
DK
Denmark
Prior art keywords
morphine
pharmaceutically acceptable
acceptable salt
pharmaceutical formulation
combinations
Prior art date
Application number
DK200101859A
Other languages
Danish (da)
English (en)
Inventor
Raja G Achari
Charanjit R Behl
Jorge C Demeireles
Dua Ramneik
Anthony P Sileno
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of DK200101859A publication Critical patent/DK200101859A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK200101859A 1999-06-16 2001-12-12 Farmaceutiske formuleringer og fremgangsmåder omfattende intranasal morfin DK200101859A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
PCT/US2000/014157 WO2000076506A1 (fr) 1999-06-16 2000-05-23 Formulations pharmaceutiques et procedes comprenant de la morphine s'administrant par voie intra-nasale

Publications (1)

Publication Number Publication Date
DK200101859A true DK200101859A (da) 2001-12-12

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200101859A DK200101859A (da) 1999-06-16 2001-12-12 Farmaceutiske formuleringer og fremgangsmåder omfattende intranasal morfin

Country Status (30)

Country Link
US (1) US6677346B1 (fr)
EP (2) EP1183027A4 (fr)
JP (1) JP2003501467A (fr)
KR (1) KR20020016831A (fr)
AU (1) AU774175B2 (fr)
BG (1) BG106221A (fr)
BR (1) BR0012082A (fr)
CA (1) CA2374877C (fr)
CZ (1) CZ20014399A3 (fr)
DE (1) DE10084709T1 (fr)
DK (1) DK200101859A (fr)
EE (1) EE200100677A (fr)
ES (1) ES2197792B1 (fr)
FI (1) FI20012462L (fr)
GB (1) GB2367005A (fr)
HR (1) HRP20010926A2 (fr)
HU (1) HUP0201856A3 (fr)
IS (1) IS6202A (fr)
LT (1) LT4976B (fr)
LU (1) LU90859B1 (fr)
LV (1) LV12859B (fr)
MX (1) MXPA01012879A (fr)
NO (1) NO20015931L (fr)
NZ (1) NZ515783A (fr)
PL (1) PL352556A1 (fr)
SE (1) SE0104203D0 (fr)
SI (1) SI20850A (fr)
SK (1) SK18172001A3 (fr)
TR (1) TR200103613T2 (fr)
WO (1) WO2000076506A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
WO2002024116A1 (fr) * 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Préparations et médications nasales, inhalables et ophtalmiques locales à conservation spontanée
EP1418862A4 (fr) * 2001-06-29 2010-06-09 Leon J Lewandowski Therapie de sevrage individualisee en cas de dependance
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
PT2486942T (pt) 2004-11-24 2019-01-18 Meda Pharmaceuticals Inc Composições que compreendem azelastina e seus métodos de utilização
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
WO2007025286A2 (fr) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methode d'administration de medicaments pour traitement de la douleur trigeminale
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
KR101433152B1 (ko) * 2006-12-22 2014-08-22 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 안과용 약물의 전달에 유용한 젤
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
SG194927A1 (en) 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
US20150231130A1 (en) 2012-07-26 2015-08-20 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
EP3082817A4 (fr) * 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions pour administration de médicaments
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016112205A1 (fr) 2015-01-07 2016-07-14 Trigemina, Inc. Formulations d'oxytocine contenant du magnésium et procédés d'utilisation
EP4541348A3 (fr) 2016-04-12 2025-06-04 Tonix Pharma Limited Formulations d'oxytocine contenant du magnésium et procédés d'utilisation
CA3041308A1 (fr) * 2016-10-21 2018-04-26 Somniferum Labs LLC Methode, systeme et appareil pour l'administration controlee d'opioide et d'autres medicaments
CA3077627A1 (fr) * 2017-10-20 2019-04-25 Chiesi Farmaceutici S.P.A. Formulations pharmaceutiques comprenant un agoniste de recepteur d'opioide en tant que substances actives, leurs procedes de fabrication et leurs utilisations therapeutiques
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DK0689438T3 (da) * 1993-03-26 2003-09-29 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af apomorfin
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
WO1998013001A1 (fr) * 1996-09-27 1998-04-02 Nastech Pharmaceutical Company, Inc. Formulations intranasales pour favoriser le sommeil et leur procede d'utilisation

Also Published As

Publication number Publication date
US6677346B1 (en) 2004-01-13
EP1183027A4 (fr) 2003-02-05
WO2000076506A1 (fr) 2000-12-21
TR200103613T2 (tr) 2004-08-23
JP2003501467A (ja) 2003-01-14
CZ20014399A3 (cs) 2002-06-12
LT4976B (lt) 2002-12-30
CA2374877C (fr) 2004-04-13
MXPA01012879A (es) 2003-06-24
IS6202A (is) 2001-12-14
HRP20010926A2 (en) 2003-04-30
AU774175B2 (en) 2004-06-17
FI20012462A7 (fi) 2002-01-16
NZ515783A (en) 2004-05-28
SI20850A (sl) 2002-10-31
BR0012082A (pt) 2002-05-07
SE0104203L (sv) 2001-12-14
AU5156100A (en) 2001-01-02
ES2197792A1 (es) 2004-01-01
KR20020016831A (ko) 2002-03-06
SE0104203D0 (sv) 2001-12-14
BG106221A (bg) 2002-08-30
GB2367005A (en) 2002-03-27
PL352556A1 (en) 2003-08-25
GB0128383D0 (en) 2002-01-16
LU90859B1 (en) 2002-01-24
EE200100677A (et) 2003-02-17
FI20012462L (fi) 2002-01-16
HUP0201856A1 (en) 2002-09-28
CA2374877A1 (fr) 2000-12-21
NO20015931D0 (no) 2001-12-04
LV12859B (en) 2002-12-20
SK18172001A3 (sk) 2002-07-02
EP1419774A1 (fr) 2004-05-19
LT2001119A (en) 2002-07-25
NO20015931L (no) 2002-02-08
ES2197792B1 (es) 2005-05-01
HUP0201856A3 (en) 2004-12-28
DE10084709T1 (de) 2002-09-26
EP1183027A1 (fr) 2002-03-06

Similar Documents

Publication Publication Date Title
DK200101859A (da) Farmaceutiske formuleringer og fremgangsmåder omfattende intranasal morfin
RU2003132426A (ru) Фармацевтический раствор арипипразола для орального применения
KR100874876B1 (ko) 맛을 마스킹한 필름상 또는 웨이퍼상 약제
US7214381B2 (en) Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
CA2471041A1 (fr) Compositions et procedes favorisant l'administration de corticosteroides
JP4580476B2 (ja) 医薬製剤
WO2007070450A3 (fr) Produits pharmaceutiques peptidiques oraux a action rapide
CA3033897C (fr) Pulverisation de naloxone liquide
JP2022119843A5 (fr)
JP2004522802A (ja) 水溶性で風味良い複合体
JP2003512427A5 (fr)
WO2002003914A3 (fr) Formulations ameliorees d'hormones thyroidiennes
WO2001043722A3 (fr) Formulations de gels et d'aerosols pharmaceutiques et methodes pour les appliquer sur la peau et les muqueuses
CA1238275A (fr) Augmentation par le menthol de l'absorption transdermique de medicament
US4931283A (en) Menthol enhancement of transdermal drug delivery
CA2449066A1 (fr) Preparation pour film contenant de la nicotine
CA2954370A1 (fr) Aerosol sublingual de naloxone
US20170007537A1 (en) Pharmaceutical compositions of asenapine
DE19834506A1 (de) Transmucosales therapeutisches System zur Anwendung von Sildenafil
AU714913B2 (en) Intranasal formulations for promoting sleep and method of using the same
JPH10500140A (ja) 視神経の健康方法
CA2930565A1 (fr) Formulation de spray sublingual d'ondansetron
WO2014084568A1 (fr) Composition de gel topique contenant une émulsion de dexibuprofène ayant une perméabilité améliorée
JP2548686B2 (ja) 外用薬剤組成物
US20190224171A1 (en) Liquid rizatriptan compositions

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment